

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com **https:**//www.wjgnet.com

# CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page number (Without Figures): 29 Rate: 6.2 CNY per page
Editing Fee: 179.8 CNY
Ethics and relevant document handling time (Clinical and Basic Research Original Articles) <sup>1</sup> : 3 h
Rate: 60 CNY per h
Editing Fee: <u>46 CNY</u>
Ethics and relevant document handling time (Case Report and Other Types of Articles) <sup>1</sup> : 2 h
Rate: 60 CNY per hour
Editing Fee:CNY
Figure count:Figure handling time:min_Rate: 1 CNY per min
Editing Fee:CNY
XML and PDF converting time: min_Rate: 1 CNY per min
Editing Fee:CNY
Manuscript word count: 6739
Total Editing Fee: 225.8 CNY
Scientific Editor: <u>Jia-Ru Fan</u>

	Date of signature: <u>January/22/2024</u> (mor	nth/day/year)
		Comments
Item No.	Specific items for verification	Yes=[Y]
		No= [N]
	General Information of the Manuscript	
	Name of journal: World Journal of Clinical Cases	
1	Manuscript NO.: 90628	[Y]
	Column: Basic Study	
	Title: Serum urate is associated with an increased risk of	



**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

	inflammatory bowel disease: A bidirectional Mendelian	
	randomization study	
	Authors: Song Zhang, Xue Fang, Le Kang, Xiang-Yu Sui, Miao Liu,	
	Yu-Jia Luo, Shuo Fu, Zhao-Shen Li, Sheng-Bing Zhao and Yu Bai	
	Reviewer code: 07918321	
	First decision: 2023-12-14 19:44	
	Editorial Office's Comments	
	Science Editor: 1 Scientific classification: Grade C. 2 Language	
	classification: Grade B. 3 Specific comments: (1) Please provide the	
	Biostatistics statement. (2) Please provide the Institutional review	
	board statement. (3) Please provide the Informed consent statement.	
	(4) Please provide the Figures cited in the original manuscript in the	
	form of PPT. All text can be edited, including A,B, arrows, etc. With	
	respect to the reference to the Figure, please verify if it is an original	
	image created for the manuscript, if not, please provide the source	
2	of the picture and the proof that the Figure has been authorized by	[Y]
	the previous publisher or copyright owner to allow it to be	
	redistributed. All legends are incorrectly formatted and require a	
	general title and explanation for each figure. Such as Figure 1 title.	
	A: ; B: ; C: . (5) Please obtain permission for the use of picture(s). If	
	an author of a submission is re-using a figure or figures published	
	elsewhere, or that is copyrighted, the author must provide	
	documentation that the previous publisher or copyright holder has	
	given permission for the figure to be re-published, and correctly	
	indicate the reference source and copyrights. For example, "Figure 1	



# Baishideng Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

https://www.wjgnet.com

Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]". And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable. (6) Please don't include any \*, #, †, §, ‡, ¥, @....in your manuscript; Please use superscript numbers for illustration; and for statistical significance, please use superscript letters. Statistical significance is expressed as aP < 0.05, bP < 0.01 (P > 0.05 usually does not need to be denoted). If there are other series of P values, cP < 0.05 and dP < 0.01 are used, and a third series of P values is expressed as eP < 0.05 and fP < 0.01. (7) Please add the Core tip section. The number of words should be controlled between 50-100 words. (8) The "Article Highlights" section is missing. Please add the "Article Highlights" section at the end of the main text (and directly before the References). (9) Please provide all fund documents. 4 Recommendation: Transfer to other BPG journals (World Journal of Gastrointestinal Surgery).



**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

	Company Editor-in-Chief: I recommend the manuscript to be	
	published in the World Journal of Clinical Cases. When revising	
	the manuscript, it is recommended that the author supplement and	
	improve the highlights of the latest cutting-edge research results,	
	thereby further improving the content of the manuscript. To this	
	end, authors are advised to apply PubMed, or a new tool, the RCA,	
	of which data source is PubMed. RCA is a unique artificial	
	intelligence system for citation index evaluation of medical science	
	and life science literature. In it, upon obtaining search results from	
	the keywords entered by the author, "Impact Index Per Article"	
	under "Ranked by" should be selected to find the latest highlight	
	articles, which can then be used to further improve an article under	
	preparation/peer-review/revision. Please visit our RCA database	
	for more information at:	
	https://www.referencecitationanalysis.com/, or visit PubMed at:	
	https://pubmed.ncbi.nlm.nih.gov/.	
3	The fixed headings are copied.	[Y]
	The title concisely summarizes the main topic of the study and is	
	not too long (no more than 18 words). Words such as 'exploration',	
4	'research', 'analysis', 'observation', and 'investigation' are avoided.	[Y]
	The title does not start with 'The' and does not include any Arabic	
	numbers or uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[Y]
	The authors' full family (sur)names and full/abbreviated first	
6	names are listed on the title page and are consistent with those	[Y]
	listed in the signed BPG Copyright License Agreement form.	
	0 -17 0	



**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

7	The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names.  e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents and analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and	[Y]
	Wang CL, Liang L and Fu JF wrote the manuscript. All authors have read and approve the final manuscript."	
8	The 'Supported by' statement describes the source(s) of financial support and includes the corresponding identification number(s) and program ID(s) if available, and contains no spelling errors.	[Y]
9	The 'Corresponding author' passage provides the corresponding author's full first and family (sur)names, abbreviated title (e.g., MD, PhD), affiliated institute's name and complete postal address (including zip code) and e-mail (written in all lowercase), and contains no spelling errors.	[Y]
10	The Manuscript Tracking information ( <i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors.	[Y]
11	The Abstract section is formatted according to the article-specific style (structured $vs$ unstructured) and word count thresholds, as follows:  Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight:  Non-structured abstract that is no less than 200 words.  Field of Vision, Case Report and Letter to the Editor:	[Y]



**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

	Non-structured abstract that is no less than 150 words.	
	Research articles: Structured abstract with subsections for AIM (no	
	more than 20 words); METHODS (no less than 80 words); RESULTS	
	(no less than 120 words); and CONCLUSION (no more than 26	
	words).	
	The 'Key words' list provides 5-10 keywords that reflect the main	
12	content of the study. The first letter of each keyword is capitalized,	[Y]
	and each keyword is separated by a semicolon.	
	The "citation" contains authors' names and manuscript title. The	
	name of the first author should be typed in bold letters; the family	
	(sur) name of all authors should be typed with the first letter	
	capitalized, followed by their abbreviated first and middle initials.	
13	For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick	[Y]
	Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,	
	Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes	
	mellitus increases the risk of gastric cancer: A meta-analysis. World J	
	Gastroenterol 2019; In press	
	The 'Core tip' provides a summary (less than 100 words) of the	
14	study that outlines the most innovative and important arguments	D./I
14	and core contents of the paper and will serve to effectively attract	[Y]
	readers.	
	The 'INTRODUCTION' section clearly describes the relevant	
	background information for the study. Only the most relevant and	
	current (within the past 5 years) literature is cited, with the	
	exception of rare instances of seminal literature citations. All	
15	technical terms and/or abbreviations are explained and/or defined,	[Y]
	with the full name of abbreviations given upon first appearance in	
	the text and the abbreviation presented in parentheses [i.e.,	
	"computed tomography (CT)"]. First-person pronouns (e.g., 'I',	
	'we') are used appropriately to clearly indicate the work performed	



**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

	by the author(s). When weaknesses of previous studies are described in the text to highlight the innovations related to the current study, the information is presented carefully.	
16	The 'MATERIALS AND METHODS' section clearly and accurately describes all materials and methods used to obtain the data presented in the article and is adequate for a reader to repeat the study.	[Y]
17	The 'RESULTS' section concisely describes the observational and experimental results. Representative data and data that have scientific significance are emphasized. Data is presented in either the text, a table or figure ( <i>i.e.</i> , chart, diagram, graph or image), but is not repeated among each. Information presented in the tables and figures clearly describes the trends, meaning, and inferences. Results described in textual form are accurate, concise and clear.	[Y]
18	Statistical symbols are accurate. Statistical significance is expressed as ${}^aP < 0.05$ , ${}^bP < 0.01$ ( $P > 0.05$ usually does not need to be denoted). If there are other series of $P$ values, ${}^cP < 0.05$ and ${}^dP < 0.01$ are used, and a third series of $P$ values is expressed as ${}^eP < 0.05$ and ${}^fP < 0.01$ . Statistical data is expressed as mean $\pm$ SD or mean $\pm$ SE.	[Y]



**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

The 'DISCUSSION' section (1) describes the main purpose and hypothesis of the study; (2) summarizes the most important results; (3) illustrates and explains the results (but does not simply repeat the data) and draws conclusions or inferences based on the results; (4) points out the limitations of the study and their impact on the results, as well as proposes further advice on future research topic(s) or direction(s); and (5) describes the theoretical significance and practical value of the findings.  The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support (i.e., providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services (i.e., useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text, For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e.,, "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Mal"! reported", "Pan et al <sup>[2-8]</sup> indicated"; "PCR has a high sensitivity <sup>[6,8]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (e.g., Pan et al <sup>[2-8]</sup> , please see reference [8]).			
(3) illustrates and explains the results (but does not simply repeat the data) and draws conclusions or inferences based on the results;  (4) points out the limitations of the study and their impact on the results, as well as proposes further advice on future research topic(s) or direction(s); and (5) describes the theoretical significance and practical value of the findings.  The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support (i.e., providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services (i.e., useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e., "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Mal <sup>[1]</sup> reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6-0]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		The 'DISCUSSION' section (1) describes the main purpose and	
the data) and draws conclusions or inferences based on the results;  (4) points out the limitations of the study and their impact on the results, as well as proposes further advice on future research topic(s) or direction(s); and (5) describes the theoretical significance and practical value of the findings.  The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support (i.e., providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services (i.e., useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e., "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Mal" reported", "Pan et al". No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		hypothesis of the study; (2) summarizes the most important results;	
(4) points out the limitations of the study and their impact on the results, as well as proposes further advice on future research topic(s) or direction(s); and (5) describes the theoretical significance and practical value of the findings.  The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support (i.e., providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services (i.e., useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  21 The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e., "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Mal" reported", "Pan et al". For indicated"; "PCR has a high sensitivity [6,9]." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		(3) illustrates and explains the results (but does not simply repeat	
(4) points out the limitations of the study and their impact on the results, as well as proposes further advice on future research topic(s) or direction(s); and (5) describes the theoretical significance and practical value of the findings.  The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support (i.e., providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services (i.e., useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e., "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Mal" reported", "Pan et al". No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text	10	the data) and draws conclusions or inferences based on the results;	[5/]
topic(s) or direction(s); and (5) describes the theoretical significance and practical value of the findings.  The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support (i.e., providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services (i.e., useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e.,, "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported," "Pan et al <sup>[2-5]</sup> indicated,"; "PCR has a high sensitivity <sup>[6-9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text	19	(4) points out the limitations of the study and their impact on the	[1]
and practical value of the findings.  The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support (i.e., providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services (i.e., useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e.,, "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Mal <sup>[1]</sup> reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ," No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		results, as well as proposes further advice on future research	
The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support ( <i>i.e.</i> , providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services ( <i>i.e.</i> , useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name ( <i>i.e.</i> ., "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Mal <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		topic(s) or direction(s); and (5) describes the theoretical significance	
individuals or organizations for technical support ( <i>i.e.</i> , providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services ( <i>i.e.</i> , useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  21 The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name ( <i>i.e.</i> ,, "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6-9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		and practical value of the findings.	
instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services ( <i>i.e.</i> , useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  21 The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name ( <i>i.e.</i> ,, "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		The 'ACKNOWLEDGEMENTS' section expresses gratitude to any	
assistance in experimental work), non-technical services ( <i>i.e.</i> , useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name ( <i>i.e.</i> , "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Mal <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		individuals or organizations for technical support (i.e., providing	
assistance in experimental work), non-technical services (i.e., useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e., "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text	20	instrumentation, equipment or experimental materials, and/or	
auxiliary work.  The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e., "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity [6-9]." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text	20	assistance in experimental work), non-technical services (i.e., useful	[Y]
The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e.,, "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		inspiration, suggestions, guidance, or review), and/or any other	
original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e., "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		auxiliary work.	
original articles in accordance with the specified format.  The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name ( <i>i.e.</i> ,, "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text	24	The 'ARTICLE HIGHLIGHTS' section provides comments for	D/I
style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name ( <i>i.e.</i> ,, "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text	21	original articles in accordance with the specified format.	[Y]
order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name ( <i>i.e.</i> ,, "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		The 'REFERENCES' section lists the references in the Vancouver	
where the author's name is indicated in the text, a superscript number should be placed following the name ( <i>i.e</i> , "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		style. This style uses Arabic numeral in-text citations based on the	
number should be placed following the name ( <i>i.e</i> , "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		order of the first appearance of a source in the text. For citations	
citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		where the author's name is indicated in the text, a superscript	
be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		number should be placed following the name (i.e, "Pang et al"). For	
reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text	22	citations where no author is indicated, a superscript number should	
sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup>	[Y]
reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high	
experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text		sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the	
style of reference citations in tables is the same as that in the text		reference number is described in the text; for example, "The	
		experimental method used has been described in reference [8]." The	
(e.g., Pan et al <sup>[2-5]</sup> , please see reference [8]).		style of reference citations in tables is the same as that in the text	
		(e.g., Pan et al <sup>[2-5]</sup> , please see reference [8]).	



**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

	Journal references have been verified to ensure that there are no	
	duplicate references and that the PMID numbers are correct. For	
	references not yet included in PubMed: the name of Chinese	
22	journals is spelled out using Chinese Pinyin, with the first letter of	[N]
23	each word capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of	[Y]
	journals in other languages are listed according to indexing	
	information retrieved from Google. Book references are presented	
	with all the information relevant to the electronic version.	
	The number of cited references is appropriate for the article type, as	
	follows:	
24	Commentary: no less than 50;	5.0
24	Review: no less than 100;	[Y]
	Article: no less than 30/26;	
	Case Report and Letter to the Editor: no less than 1.	
	The ethics-related statements are provided in accordance with the	
25	manuscript type (e.g., Manuscript NoInstitutional review board	[Y]
	statement, Manuscript NoAnimal care and use statement, etc.).	
	The names of the peer reviewers and the scientific editor are present	
26	at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang	[Y]
	JL).	
	The order and numerical labeling of tables and figures is consistent	
	with their appearance and presentation in the text. Symbols in	
27	tables (e.g., +, -, $\times$ , $\div$ , *) correctly correspond to the definitions in the	
	footnotes. Only one legend is provided for each multi-panel figure	[1/]
	consisting of color graphs, black and white graphs, or line graphs	[Y]
	that depicts data of the same theme. For example: Figure 1	
	Pathological changes in atrophic gastritis tissue before and after	
	treatment. A:; B:; C:; D:; E:; F:	
28	Split pictures include flow charts, line graphs, histograms, and	[Y]
20	graphs including text. Unsplit pictures include meta-analysis	[1]



**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.  The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.  The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoInstitutional statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoInstitutional review board statement); (6) Institutional review board approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional review board statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement).  The language certificate provided by authors who are non-native speakers of English meets the BPG requirements (file name: Manuscript NoEnglish meets the BPG requirements (file name: Manuscript NoCopyright license agreement).		ti pop tid d	
according to the peer-reviewers' comments.  The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.  The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: tatement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInstitutional animal care and use committee statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement).		diagrams, PCR amplification curves, and survival curves.	
The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.  The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee Animal Care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement; e.g., 870-Copyright license agreement).	29	The author(s) highlighted the changes made to the manuscript	[Y]
the changes made to the manuscript.  The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement).  The language certificate provided by authors who are non-native		according to the peer-reviewers' comments.	
the changes made to the manuscript.  The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement) icense agreement; e.g., 870-Copyright license agreement).	30	The responses to the peer-reviewers' comments are consistent with	[Y]
NoReview; e.g., 870- Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).		the changes made to the manuscript.	[+]
The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoConflict review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).  The language certificate provided by authors who are non-native		The revised manuscript is provided (file name: Manuscript	
Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement):  The language certificate provided by authors who are non-native		NoReview; <i>e.g.</i> , 870- Review).	
Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional review board statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., [Y] 870-Copyright license agreement).	24	The letter of peer-reviewers' comments is provided (file name:	D.O.
NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).	31	Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).	[Y]
The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).  The language certificate provided by authors who are non-native		The response letter is provided (file name: Manuscript	
Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).		NoAnswering reviewers; <i>e.g.</i> , 870-Answering reviewers).	
Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).		The related ethics and relevant documents are provided, such as (1)	
approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).			
form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).			
NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., [Y] 870-Copyright license agreement).			
name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).			
trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).  The language certificate provided by authors who are non-native		, , ,	
registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).			
or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., [Y] 870-Copyright license agreement).	32		[Y]
statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).  The language certificate provided by authors who are non-native			
approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).  The language certificate provided by authors who are non-native		· ·	
NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., [Y] 870-Copyright license agreement).  The language certificate provided by authors who are non-native		, , ,	
Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., [Y] 870-Copyright license agreement).  The language certificate provided by authors who are non-native		, ,	
Manuscript NoInformed consent statement).  All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).  The language certificate provided by authors who are non-native			
All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement).  The language certificate provided by authors who are non-native			
name: Manuscript NoCopyright license agreement; e.g., [Y] 870-Copyright license agreement).  The language certificate provided by authors who are non-native		,	
870-Copyright license agreement).  The language certificate provided by authors who are non-native			
The language certificate provided by authors who are non-native	33		[Y]
34		870-Copyright license agreement).	
speakers of English meets the BPG requirements (file name:	34	The language certificate provided by authors who are non-native	[Y]
		speakers of English meets the BPG requirements (file name:	r+1



**Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

	Managiri NI, I and a different control of the contr	
	Manuscript NoLanguage certificate; <i>e.g.</i> , 870-Language certificate).	
	The photos licensed in the Agreement for Use of Personal Photos	
35	are consistent with those in the paper (file name: Manuscript	[N]
	NoAgreement for use of personal photos; e.g., 870-Agreement for	6-1
	use of personal photos).	
	This document (Checklist of Responsibilities for Scientific Editors)	
36	has been saved under the file name: manuscript NoScientific	[Y]
	editor work list (e.g., 870-Scientific editor work list).	
	A CrossCheck investigation (an effective tool for detecting unoriginal	
	content, enabling our editors to preserve the journal's integrity and	
	the authors' copyright) has been performed for the manuscript via	
	the website: http://www.ithenticate.com/. The results document	
	contains the following information for the manuscript: "Name of	
37	journal", "Manuscript No.", "Columns", "Title" and "Author list".	[Y]
	The Figure of the <i>CrossCheck</i> results is saved in JPEG format (.jpg) at	
	$1440 \times 680$ pixel resolution. The PDF of the <i>CrossCheck</i> results has	
	been saved under the file name: manuscript No CrossCheck report	
	(e.g., 870-CrossCheck report). The Google searches have also been	
	performed to further ensure publication of original content.	
	The text of the manuscript is typed in Book Antiqua font, 12 pt, with	
38	1.5 line spacing.	[Y]
	The primary responsibilities of our scientific editors include carefully	y checking the
Responsibilities of scientific editors		
	grammar, punctuation and wording; (2) suitability of tables, figures, figure data and	
	legends; (3) accurate and appropriate presentation of symbols (e.g. +, -, ×, ÷, %, *) in	
	tables and figures; and (4) complete and comprehensive revision of t	he manuscript
	according to the reviewers' comments.	-
	according to the reviewers confinents.	



# Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

E-mail: office@baishideng.com

**Telephone:** +1-925-399-1568

https://www.wjgnet.com

Publication
process

Manuscript reception and registration→Initial review by scientific editor→Peer review→End of peer review→First round of meeting evaluation→To be accepted→Revision by the author(s)→Second round of meeting evaluation→To be accepted/revised/rejected→Final review by the Editor-in-Chief (final quality control for academic content and language quality)→Final acceptance and charging of publication fee-Language editing-Production-Proofreading by scientific editor→Proofreading by deputy editor→Final review by Editor-in-Chief→Release of online open-access papers in electronic form on the BPG website-Release of online papers on PubMed Central→Delivery of high-quality PDF reprints to the author(s) $\rightarrow$ End of the publication process.

## <sup>1</sup>Ethics and Relevant Document Handling Time

# **Notes**

For the checking of the ethics and relevant document, the editing fee should be calculated independently to the Scientific Editor. The handling time of the ethics and relevant documents for clinical and basic researches is calculated as 3 hours, for case reports and other types of manuscript is calculated as 2 hours.

If any errors are found in ethics and relevant document after a manuscript is published, a fine of 500 CNY will be imposed on the Scientific Editor for the manuscript, which will be deducted from the Scientific Editor's Welfare provided by the Baishideng Publishing Group.